Andorra

Andorra

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
0.91 (0.75 - 1.07) 2019 Modelled IHME
0.92 (0.76 - 1.06) 2018 Modelled IHME
0.92 (0.77 - 1.07) 2017 Modelled IHME
0.93 (0.79 - 1.08) 2016 Modelled IHME
0.95 (0.79 - 1.10) 2015 Modelled IHME
0.97 (0.81 - 1.11) 2014 Modelled IHME
0.98 (0.82 - 1.13) 2013 Modelled IHME
1 (0.83 - 1.14) 2012 Modelled IHME
1.01 (0.84 - 1.16) 2011 Modelled IHME
1.02 (0.84 - 1.18) 2010 Modelled IHME
1.03 (0.86 - 1.20) 2009 Modelled IHME
1.05 (0.87 - 1.21) 2008 Modelled IHME
1.06 (0.88 - 1.23) 2007 Modelled IHME
1.07 (0.88 - 1.24) 2006 Modelled IHME
1.08 (0.89 - 1.26) 2005 Modelled IHME
1.09 (0.89 - 1.27) 2004 Modelled IHME
1.1 (0.90 - 1.30) 2003 Modelled IHME
1.12 (0.90 - 1.31) 2002 Modelled IHME
1.13 (0.91 - 1.34) 2001 Modelled IHME
1.14 (0.91 - 1.35) 2000 Modelled IHME
1.14 (0.93 - 1.35) 1999 Modelled IHME
1.14 (0.93 - 1.34) 1998 Modelled IHME
1.15 (0.94 - 1.35) 1997 Modelled IHME
1.15 (0.95 - 1.35) 1996 Modelled IHME
1.16 (0.96 - 1.37) 1995 Modelled IHME
1.16 (0.96 - 1.36) 1994 Modelled IHME
1.17 (0.97 - 1.36) 1993 Modelled IHME
1.18 (0.97 - 1.37) 1992 Modelled IHME
1.18 (0.97 - 1.39) 1991 Modelled IHME
1.19 (0.96 - 1.41) 1990 Modelled IHME
0.64 (0.04 - 10.20) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.04 (0.03 - 0.06) 2019 Modelled IHME
0.04 (0.03 - 0.06) 2018 Modelled IHME
0.04 (0.03 - 0.06) 2017 Modelled IHME
0.05 (0.03 - 0.06) 2016 Modelled IHME
0.05 (0.04 - 0.07) 2015 Modelled IHME
0.05 (0.04 - 0.07) 2014 Modelled IHME
0.05 (0.03 - 0.07) 2013 Modelled IHME
0.05 (0.03 - 0.06) 2012 Modelled IHME
0.05 (0.03 - 0.06) 2011 Modelled IHME
0.05 (0.03 - 0.06) 2010 Modelled IHME
0.06 (0.04 - 0.07) 2009 Modelled IHME
0.08 (0.05 - 0.10) 2008 Modelled IHME
0.1 (0.07 - 0.14) 2007 Modelled IHME
0.12 (0.08 - 0.17) 2006 Modelled IHME
0.13 (0.09 - 0.18) 2005 Modelled IHME
0.13 (0.09 - 0.18) 2004 Modelled IHME
0.13 (0.09 - 0.18) 2003 Modelled IHME
0.13 (0.09 - 0.18) 2002 Modelled IHME
0.13 (0.08 - 0.18) 2001 Modelled IHME
0.13 (0.08 - 0.18) 2000 Modelled IHME
0.13 (0.09 - 0.18) 1999 Modelled IHME
0.14 (0.10 - 0.19) 1998 Modelled IHME
0.16 (0.11 - 0.21) 1997 Modelled IHME
0.18 (0.12 - 0.24) 1996 Modelled IHME
0.2 (0.14 - 0.27) 1995 Modelled IHME
0.24 (0.17 - 0.32) 1994 Modelled IHME
0.3 (0.21 - 0.40) 1993 Modelled IHME
0.38 (0.27 - 0.50) 1992 Modelled IHME
0.47 (0.34 - 0.62) 1991 Modelled IHME
0.57 (0.41 - 0.75) 1990 Modelled IHME
0.08 (0 - 1.65) 2015 Modelled WHO
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
12 (8 - 17) 2019 Modelled IHME
12 (8 - 17) 2018 Modelled IHME
12 (8 - 17) 2017 Modelled IHME
12 (8 - 17) 2016 Modelled IHME
12 (8 - 17) 2015 Modelled IHME
12 (8 - 17) 2014 Modelled IHME
12 (8 - 17) 2013 Modelled IHME
12 (8 - 17) 2012 Modelled IHME
12 (8 - 17) 2011 Modelled IHME
12 (8 - 17) 2010 Modelled IHME
12 (8 - 17) 2009 Modelled IHME
12 (8 - 17) 2008 Modelled IHME
12 (8 - 17) 2007 Modelled IHME
12 (8 - 17) 2006 Modelled IHME
12 (8 - 17) 2005 Modelled IHME
12 (8 - 17) 2004 Modelled IHME
12 (8 - 17) 2003 Modelled IHME
12 (8 - 18) 2002 Modelled IHME
12 (9 - 18) 2001 Modelled IHME
13 (9 - 18) 2000 Modelled IHME
13 (9 - 18) 1999 Modelled IHME
13 (9 - 19) 1998 Modelled IHME
13 (9 - 19) 1997 Modelled IHME
13 (9 - 19) 1996 Modelled IHME
13 (9 - 19) 1995 Modelled IHME
13 (9 - 19) 1994 Modelled IHME
13 (9 - 19) 1993 Modelled IHME
13 (9 - 19) 1992 Modelled IHME
13 (9 - 19) 1991 Modelled IHME
13 (9 - 20) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of HepB birth dose

Newborns
Download
Value (%) Year Type Source
94 2018 Survey/reported WHO/UNICEF
94 2017 Survey/reported WHO/UNICEF
94 2016 Survey/reported WHO/UNICEF
94 2015 Survey/reported WHO/UNICEF
94 2014 Survey/reported WHO/UNICEF
96 2013 Survey/reported WHO/UNICEF
95 2012 Survey/reported WHO/UNICEF
93 2011 Survey/reported WHO/UNICEF
94 2010 Survey/reported WHO/UNICEF
94 2009 Survey/reported WHO/UNICEF
98 2008 Survey/reported WHO/UNICEF
98 2007 Survey/reported WHO/UNICEF
98 2006 Survey/reported WHO/UNICEF
97 2005 Survey/reported WHO/UNICEF
97 2004 Survey/reported WHO/UNICEF
96 2003 Survey/reported WHO/UNICEF
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
98 2018 Survey/reported WHO/UNICEF
98 2017 Survey/reported WHO/UNICEF
94 2016 Survey/reported WHO/UNICEF
94 2015 Survey/reported WHO/UNICEF
95 2014 Survey/reported WHO/UNICEF
94 2013 Survey/reported WHO/UNICEF
96 2012 Survey/reported WHO/UNICEF
99 2011 Survey/reported WHO/UNICEF
96 2010 Survey/reported WHO/UNICEF
96 2009 Survey/reported WHO/UNICEF
97 2008 Survey/reported WHO/UNICEF
91 2007 Survey/reported WHO/UNICEF
84 2006 Survey/reported WHO/UNICEF
79 2005 Survey/reported WHO/UNICEF
77 2004 Survey/reported WHO/UNICEF
81 2003 Survey/reported WHO/UNICEF
84 2002 Survey/reported WHO/UNICEF
84 2001 Survey/reported WHO/UNICEF
84 2000 Survey/reported WHO/UNICEF
75 1999 Survey/reported WHO/UNICEF
80 1998 Survey/reported WHO/UNICEF
75 1997 Survey/reported WHO/UNICEF
Showing out of
Show more

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2014 Survey/reported Harm Reduction International, 2016
HBV elimination goal
HBV National Action Plan
HepB birth dose policy
Yes
Year of birth dose introduction
1998
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
Most (61-100%)

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
0.93 (0.77 - 1.14) 2019 Modelled IHME
0.93 (0.77 - 1.13) 2018 Modelled IHME
0.92 (0.76 - 1.13) 2017 Modelled IHME
0.91 (0.75 - 1.11) 2016 Modelled IHME
0.89 (0.73 - 1.08) 2015 Modelled IHME
0.88 (0.72 - 1.07) 2014 Modelled IHME
0.87 (0.72 - 1.06) 2013 Modelled IHME
0.86 (0.71 - 1.05) 2012 Modelled IHME
0.85 (0.70 - 1.05) 2011 Modelled IHME
0.84 (0.69 - 1.04) 2010 Modelled IHME
0.83 (0.68 - 1.02) 2009 Modelled IHME
0.82 (0.68 - 1.01) 2008 Modelled IHME
0.81 (0.67 - 0.99) 2007 Modelled IHME
0.8 (0.66 - 0.98) 2006 Modelled IHME
0.8 (0.66 - 0.98) 2005 Modelled IHME
0.8 (0.66 - 0.98) 2004 Modelled IHME
0.8 (0.66 - 0.99) 2003 Modelled IHME
0.81 (0.66 - 0.99) 2002 Modelled IHME
0.81 (0.67 - 0.99) 2001 Modelled IHME
0.81 (0.66 - 1) 2000 Modelled IHME
0.81 (0.66 - 0.98) 1999 Modelled IHME
0.79 (0.66 - 0.97) 1998 Modelled IHME
0.78 (0.65 - 0.95) 1997 Modelled IHME
0.77 (0.63 - 0.93) 1996 Modelled IHME
0.76 (0.62 - 0.92) 1995 Modelled IHME
0.75 (0.61 - 0.91) 1994 Modelled IHME
0.74 (0.60 - 0.90) 1993 Modelled IHME
0.73 (0.59 - 0.90) 1992 Modelled IHME
0.73 (0.59 - 0.89) 1991 Modelled IHME
0.72 (0.58 - 0.88) 1990 Modelled IHME
Showing out of
Show more

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
38 (29 - 48) 2019 Modelled IHME
39 (29 - 48) 2018 Modelled IHME
39 (29 - 48) 2017 Modelled IHME
39 (29 - 48) 2016 Modelled IHME
39 (30 - 48) 2015 Modelled IHME
39 (29 - 48) 2014 Modelled IHME
38 (29 - 47) 2013 Modelled IHME
38 (29 - 47) 2012 Modelled IHME
38 (28 - 47) 2011 Modelled IHME
37 (28 - 46) 2010 Modelled IHME
36 (27 - 46) 2009 Modelled IHME
36 (27 - 45) 2008 Modelled IHME
36 (27 - 45) 2007 Modelled IHME
36 (26 - 45) 2006 Modelled IHME
35 (26 - 45) 2005 Modelled IHME
35 (26 - 44) 2004 Modelled IHME
35 (26 - 44) 2003 Modelled IHME
35 (26 - 44) 2002 Modelled IHME
35 (25 - 44) 2001 Modelled IHME
35 (25 - 44) 2000 Modelled IHME
34 (25 - 44) 1999 Modelled IHME
34 (25 - 44) 1998 Modelled IHME
34 (24 - 44) 1997 Modelled IHME
34 (24 - 44) 1996 Modelled IHME
34 (24 - 44) 1995 Modelled IHME
34 (24 - 43) 1994 Modelled IHME
33 (24 - 43) 1993 Modelled IHME
33 (24 - 43) 1992 Modelled IHME
33 (24 - 43) 1991 Modelled IHME
33 (24 - 43) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2014 Survey/reported Harm Reduction International, 2016
HBV elimination goal
HBV National Action Plan
HepB birth dose policy
Yes
Year of birth dose introduction
1998
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
Most (61-100%)

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
0.91 (%)
2019
(0.75 - 1.07(%))
IHME
HCV (RNA/cAg+)
0.93 (%)
2019
(0.77 - 1.14(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
3
2019
(2 - 4)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
7
2019
(5 - 10)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.04 (%)
2019, latest modelled
(0.03 - 0.06(%))
IHME

Prevalence PWID

No data available

Birth dose vaccination coverage (national)

Survey/surveillance

HBV
94 (%)
2018
WHO/UNICEF

No. of syringes/PWID/year

Survey/surveillance

No data available
Eligible for HBV generic medicines
Eligible for HCV generic medicines